Surgical Science Q4 2023: Soft Q4 numbers - Redeye

Redeye provides its initial take on Surgical Science’s Q4 2023 report, which broadly underperformed our expectations. We judge that notable positives from the report include a strong gross margin and solid software licence sales. Notable negatives include weak fourth-quarter net sales and margins, diverging from the company’s historical Q4-heavy seasonality. We judge the quarterly numbers underline how even though Surgical Science seems to be a quality company with healthy long-term prospects, the business features considerable sequential volatility.

Länk till analysen i sin helhet: https://www.redeye.se/research/983437/surgical-science-q4-2023-soft-q4-numbers?utm_source=finwire&utm_medium=RSS